One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Addressing Serious Illness Care in Medicare Advantage
Claire K. Ankuda, M.D., M.P.H., Melissa D. Aldridge, Ph.D., M.B.A., R. Tyler Braun, Ph.D., Norma B. Coe, Ph.D., David C. Grabowski, Ph.D., David J. Meyers, Ph.D., M.P.H., Andrew Ryan, Ph.D., David Stevenson, Ph.D., and Joan M. Teno, M.D.
doi : 10.1056/NEJMp2302252
Vol. 388 No. 19
Corporate Citizenship and Institutional Responses Post-Dobbs — Critical Lessons from Two Restrictive States
Justin R. Lappen, M.D., Leilah Zahedi-Spung, M.D., and Ashley R. Brant, D.O., M.P.H.
doi : 10.1056/NEJMp2302101
Ethical Conflicts for Clinicians under Tennessee Abortion Law
Allison M. McCarthy, Ph.D., Elise W. Boos, M.D., Uchenna E. Anani, M.D., and Ellen W. Clayton, M.D., J.D.
doi : 10.1056/NEJMp2303213
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia
Barbara Eichhorst, M.D., Carsten U. Niemann, M.D., Arnon P. Kater, M.D., Moritz Fürstenau, M.D., Julia von Tresckow, M.D., Can Zhang, Ph.D., Sandra Robrecht, Ph.D., Michael Gregor, M.D., Gunnar Juliusson, M.D., Patrick Thornton, M.D., Philipp B. Staber, M.D., Tamar Tadmor, M.D.,
doi : 10.1056/NEJMoa2213093
Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking.
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy
Matthew Greenhawt, M.D., Sayantani B. Sindher, M.D., Julie Wang, M.D., Michael O’Sullivan, M.D., George du Toit, M.D., Edwin H. Kim, M.D., Deborah Albright, M.D., Sara Anvari, M.D., Nicolette Arends, M.D., Peter D. Arkwright, Ph.D., Philippe Bégin, M.D., Ph.D., Katharina Blumchen, M.D., Thierry Bourrier, M.D., Terri Brown-Whitehorn, M.D., Heather Cassell, M.D., Edmond S. Chan, M.D., Christina E. Ciaccio, M.D., Antoine Deschildre, M.D., Amandine Divaret-Chauveau, M.D., Stacy L. Dorris, M.D., Morna J. Dorsey, M.D., Thomas Eiwegger, M.D., Michel Erlewyn-Lajeunesse, D.M., David M. Fleischer, M.D., Lara S. Ford, M.B., B.S., M.P.H., Maria Garcia-Lloret, M.D., Lisa Giovannini-Chami, M.D., Ph.D., Jonathan O. Hourihane, D.M., Nicola Jay, M.B., B.S., Stacie M. Jones, M.D., Leigh Ann Kerns, M.D., Kirsten M. Kloepfer, M.D., Stephanie Leonard, M.D., Guillaume Lezmi, M.D., Ph.D., Jay A. Lieberman, M.D., Jeanne Lomas, D.O., Melanie Makhija, M.D., Christopher Parrish, M.D., Jane Peake, M.B., B.S., Kirsten P. Perrett, M.B., B.S., Ph.D., Daniel Petroni, M.D., Ph.D., Wolfgang Pfützner, M.D., Jacqueline A. Pongracic, M.D., Patrick Quinn, M.B., B.S., Rachel G. Robison, M.D., Georgiana Sanders, M.D., Lynda Schneider, M.D., Hemant P. Sharma, M.D., M.H.S., Juan Trujillo, M.D., Paul J. Turner, M.D., Ph.D., Katherine Tuttle, M.D., Julia E. Upton, M.D., Pooja Varshney, M.D., Brian P. Vickery, M.D., Christian Vogelberg, M.D., Brynn Wainstein, M.B., Ch.B., Ph.D., Robert A. Wood, M.D., Katharine J. Bee, Ph.D., Dianne E. Campbell, M.D., Ph.D., Todd D. Green, M.D., Rihab Rouissi, M.D., Aurélie Peillon, M.S., Henry T. Bahnson, M.P.H., Timothée Bois, M.Sc., Hugh A. Sampson, M.D., and A. Wesley Burks, M.D.
doi : 10.1056/NEJMoa2212895
No approved treatment for peanut allergy exists for children younger than 4 years of age, and the efficacy and safety of epicutaneous immunotherapy with a peanut patch in toddlers with peanut allergy are unknown.
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
Toni K. Choueiri, M.D., Thomas Powles, M.D., Laurence Albiges, M.D., Ph.D., Mauricio Burotto, M.D., Cezary Szczylik, M.D., Ph.D., Bogdan Zurawski, M.D., Ph.D., Eduardo Yanez Ruiz, M.D., Marco Maruzzo, M.D., Ph.D., Alberto Suarez Zaizar, M.D., Luis E. Fein, M.D., Fabio A. Schutz, M.D., Daniel Y.C. Heng, M.D., Fong Wang, M.D., Ph.D., Fabio Mataveli, M.D., Ph.D., Yu-Lin Chang, M.S., Maximiliano van Kooten Losio, M.D., Ph.D., Cristina Suarez, M.D., Ph.D., and Robert J. Motzer, M.D. for the COSMIC-313 Investigators*
doi : 10.1056/NEJMoa2212851
The efficacy and safety of treatment with cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal-cell carcinoma are unknown.
Racial Inequality in Receipt of Medications for Opioid Use Disorder
Michael L. Barnett, M.D., Ellen Meara, Ph.D., Terri Lewinson, Ph.D., M.S.W., Brianna Hardy, B.S., Deanna Chyn, M.P.H., Moraa Onsando, M.D., M.P.H., Haiden A. Huskamp, Ph.D., Ateev Mehrotra, M.D., M.P.H., and Nancy E. Morden, M.D., M.P.H.
doi : 10.1056/NEJMsa2212412
Since 2010, Black persons in the United States have had a greater increase in opioid overdose–related mortality than other groups, but national-level evidence characterizing racial and ethnic disparities in the use of medications for opioid use disorder (OUD) is limited.
Human Papillomavirus Vaccination
Lauri E. Markowitz, M.D., and Elizabeth R. Unger, M.D., Ph.D.
doi : 10.1056/NEJMcp2108502
Dietary Zinc Deficiency–Associated Dermatitis in a Child
Rohit Kothari, M.D., and Sanjay Khare, M.D.
doi : 10.1056/NEJMicm2213071
Eosinophilic Fasciitis
Katharina S. Shaw, M.D., and Ruth Ann Vleugels, M.D., M.P.H.
doi : 10.1056/NEJMicm2212023
Case 14-2023: A 31-Year-Old Man with Redness of the Right Eye
Miriam B. Barshak, M.D., Caitlin M. Dugdale, M.D., and Roberto Pineda, M.D.
doi : 10.1056/NEJMcpc2211511
Time-Limited Initial Therapy for Young, Fit Patients with CLL
Jennifer A. Woyach, M.D., and John C. Byrd, M.D.
doi : 10.1056/NEJMe2302557
Audio Interview: Ending the Covid-19 Emergency
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2305545
